scholarly journals Efficacy and Safety of Triple Drug Fixed-Dose Combination of Telmisartan, Amlodipine and Hydrochlorthiazide in the Management of Hypertension

2015 ◽  
Vol 16 (1) ◽  
pp. 18-22
Author(s):  
Faruqui A Arif ◽  
A Amlaselvam ◽  
Renuka Sriram
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Fixed Dose Combination ◽  
Antihypertensive Drug Therapy ◽  
Fixed Dose ◽  
Age Group ◽  
Optimal Management ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

Effective BP control is far away from reality in many patients in spite of advancements in many classes of antihypertensive drug therapy. Use of triple drug combination in the management of hypertension have already been established, however this study was conducted to evaluate the efficacy and safety of triple drug fixed dose combination of Telmisartan 40 mg, Amlodipine 5 mg and Hydrochlorothiazide 12.5mg. 69 hypertensive patients with seating cuff systolic blood pressure e” 160 mmHg and diastolic blood pressure e”100 mmHg were enrolled in the study. Patients were prescribed to take triple drug fixed dose combination for 120 days. Patients were evaluated on 30th, 60th and 120th days of treatment. There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 30th, 60th and 120th day of treatment mean±SD (166±18.6 mmHg vs.147±16.1, 137±14.7 and 130±13.9 mmHg) respectively. Similar to SBP, decrease in DBP was highly significant (p<0.0001) from the baseline to the 30th, 60th and 120th day of treatment (104±11.5 mmHg vs. 93.7±12.3, 89±10.2 and 84.5±8.98 mmHg respectively). Moreover at the end of the study period of 120 days 85.7% and 87.8% patients of age group >60 years and <60 years respectively achieved the JNC VIII recommended goal. This triple drug fixed dose combination of Telmisartan, Amlodipine and hydrochlorothiazide was found to be effective and safe option for the optimal management of hypertension.DOI: http://dx.doi.org/10.3329/jom.v16i1.22383 J MEDICINE 2015; 16 : 18-22

scholarly journals Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program

2021 ◽  
Vol 26 (9) ◽  
pp. 4651
Author(s):  
A. O. Konradi ◽  
A. S. Galyavich ◽  
V. V. Kashtalap ◽  
Yu. M. Lopatin ◽  
N. P. Lyamina ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Antihypertensive Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Baseline Body Mass Index ◽  
Efficacy And Safety ◽  
Open Label ◽  
Hypertensive Patients ◽  
Dose Combination

Aim. In practice, to evaluate the efficacy, safety and long-term adherence to therapy with a fixed-dose combination of ramipril/indapamide (Konsilar-D24) in patients with grade 1-2 hypertension (HTN) who have not achieved blood pressure (BP) control with prior therapy or have not taken antihypertensive therapy.Material and methods. This multicenter open-label observational program included 524 patients with grade 1-2 HTN who did not take antihypertensive therapy or did not reach the target BP level with mono or dual antihypertensive therapy, as well as patients shifted to Konsilar-D24 therapy no later than two weeks before the start of the program. All patients signed a written informed consent to participate in the program. The safety analysis set includes all patients who have taken at least one dose of a fixed-dose combination of ramipril/indapamide and have visited physician at least once during the program. The effectiveness analysis set included all patients in the safety population who completed the study in accordance with protocol (n=511). Clinical systolic blood pressure (SBP), diastolic BP (DBP) and heart rate were assessed at baseline, as well as at 0,5, 1, 3 and 6 months of treatment. A post hoc subgroup analysis of changes in BP and heart rate was performed depending on age, sex and baseline body mass index.Results. The fixed-dose combination of ramipril with indapamide significantly reduced SBP and DBP after 2-week treatment (-20,9±10,1 mm Hg; pConclusion. Despite the limitations inherent in observational studies, the KONSONANS program has demonstrated high efficacy and safety of fixed-dose combination of ramipril/indapamide taken once a day in hypertensive patients. Ramipril/indapamide fixed-dose combination therapy significantly improved BP control and achieved even lower individual target BP levels in the majority of hypertensive patients.

scholarly journals Evaluation of Efficacy and Safety of Oral Olmesartan+ Chlorthalidone Combination in the Management of Hypertension in Indian Patients

2017 ◽  
Vol 18 (1) ◽  
pp. 6-9
Author(s):  
Ashok Khanna ◽  
AA Faruqui
Keyword(s):  
Blood Pressure ◽  
Systolic Blood Pressure ◽  
Diastolic Blood Pressure ◽  
Fixed Dose Combination ◽  
Rural Populations ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Once Daily ◽  
All Cause Mortality ◽  
Dose Combination

Hypertension is the most prevalent chronic disease in India and its prevalence is rapidly increasing among urban and rural populations. Reducing blood pressure can decrease cardiovascular risk and all cause mortality. This study was conducted to assess the efficacy and safety of fixed dose combination of Olmesartan 40 mg and Chlorthalidone12.5mg. 30 hypertensive patients having systolic blood pressure ? 160 mmHg and diastolic blood pressure ?100 mmHg who were uncontrolled on monotherapy with olmesartan were enrolled in this study. The treatment period was of 60 days and patients were administered once daily fixed dose combination of Olmesartan40 mg and Chlorthalidone 12.5 mg. Patients were evaluated on 15th, 30th and 60th days of treatment.There was statistically significant (p<0.0001) decrease in systolic blood pressure from baseline to 15th, 30th and 60thday of treatmentmean±SD (179.1±13.38 mmHg vs. 169.3±13.05, 154.3±13.31, and 142.7±6.91mmHg) respectively. Similarly the diastolic blood pressure (DBP) was significantly (p<0.0001) reduced from the baseline to the 15th, 30th and 60thday of treatment (94.97±5.75mmHg vs.86.67±4.79, 80.33±1.82 and 76.7±4.32 mmHg respectively). Thus fixed dose combination of Olmesartan and Chlorthalidonewas found to be effective and safe option for the optimal management of hypertension.J MEDICINE January 2017; 18 (1) : 6-9

scholarly journals A ramipril versus ramipril/amlodipin fix kombináció egyéves perzisztenciája hypertoniás betegekben

2017 ◽  
Vol 158 (42) ◽  
pp. 1669-1673 ◽  
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Blood Pressure ◽  
Survival Analysis ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Persistence Rate ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In the treatment of hypertension avoiding adverse cardiovascular complications to achieve target blood pressure is essential. The appropriate drug selection, and if necessary to change to combination therapy, patients adherence is important which may help fixed dose combination. Aim: The aim of the authors was to investigate the one year adherence of the ramipril and ramipril/amlodipine fixed dose combination in hypertensive patients. Method: Prescriptions database of the National Health Insurance Fund in Hungary on pharmacy-claims was analysed between October 1, 2012 and September 30, 2013. The authors identified patients who filled prescriptions for ramipril monotherapy and fixed dose combinations of ramipril/amlodipine prescribed for the first time in hypertensive patients who have not received similar drugs in the previous year. To model the adherence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: 92,546 patients met the inclusion criteria. During the trial period, ramipril therapy or ramipril/amlodipine fixed dose combination was started in 82,251 and 10,295 patients, respectively. One year persistence rate in patients with ramipril was 30% and 54% in patients with ramipril/amlodipine fixed dose combination therapy. Considering only the 360-day study period, the mean duration of persistence was 189.9 days in patients on ramipril and 270.6 days on ramipril/amlodipine fixed dose combination therapy. The hazard of discontinuation was more than twofold higher during treatment with ramipril compared with the use of the ramipril/amlodipine fixed dose combination therapy (HR = 2.11 [95% CI: 2.05–2.17], p<0,001). Conclusions: There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension. The result demonstrated that ramipril/amlodipine fixed dose combination therapy has a better one year persistence rate. When the next step is necessary to achieve target blood pressure, ramipril/amlodipine fixed dose combination therapy is preferable. Orv Hetil. 2017; 158(42): 1668–1673.

HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201

2010 ◽  
Vol 28 ◽  
pp. e108
Author(s):  
MA Prieto Diaz ◽  
JA Divison Garrote ◽  
J Abellan Aleman ◽  
JL Llisterri Caro ◽  
NR Robles P&;eacute;rez-Monteoliva ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Combination Treatments ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document